CS2009 + capecitabine

CS2009 + capecitabine is an experimental combination therapy consisting of the investigational agent **CS2009** and the oral fluoropyrimidine prodrug **capecitabine**. Capecitabine is metabolized to 5-fluorouracil (5-FU), which inhibits thymidylate synthase, interfering with DNA synthesis and inhibiting cancer cell proliferation. CS2009’s precise mechanism of action is not established in public domain sources as of September 2025. Capecitabine is approved for use in various cancers, including breast and colorectal cancers, and is commonly studied in combination regimens aiming to enhance antitumor activity or overcome resistance.